TERN
Terns Pharmaceuticals Inc
$
6.530
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.700
Open
6.350
VWAP
6.53
Vol
1.37M
Mkt Cap
571.45M
Low
6.350
Amount
8.92M
EV/EBITDA(TTM)
--
Total Shares
64.68M
EV
235.87M
EV/OCF(TTM)
--
P/S(TTM)
--
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.298
+6.27%
--
--
-0.296
+23.47%
--
--
-0.307
+17.95%
Estimates Revision
The market is revising No Change the revenue expectations for Terns Pharmaceuticals, Inc. (TERN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 125.17%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.6%
In Past 3 Month
Stock Price
Go Up
+125.17%
In Past 3 Month
6 Analyst Rating
141.19% Upside
Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 15.75 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
141.19% Upside
Current: 6.530
Low
14.00
Averages
15.75
High
20.00
141.19% Upside
Current: 6.530
Low
14.00
Averages
15.75
High
20.00
Goldman Sachs
Corinne Johnson
initiated
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
2025-07-10
initiated
Reason
Goldman Sachs analyst Corinne Johnson started Terns Pharmaceuticals with an Early-Stage Biotech rating.
JMP Securities
Silvan Tuerkcan
Buy
Reiterates
$20
2025-04-21
Reason
JMP Securities
Silvan Tuerkcan
Price Target
$20
2025-04-21
Reiterates
Buy
Reason
William Blair
Andy Hsieh
Hold
Initiates
n/a
2025-02-28
Reason
William Blair
Andy Hsieh
Price Target
n/a
2025-02-28
Initiates
Hold
Reason
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
$7.5
2024-12-04
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$7.5
2024-12-04
Reiterates
Hold
Reason
Oppenheimer
Jay Olson
Buy
Maintains
$17 → $20
2024-12-04
Reason
Oppenheimer
Jay Olson
Price Target
$17 → $20
2024-12-04
Maintains
Buy
Reason
Oppenheimer raised the firm's price target on Terns Pharmaceuticals to $20 from $17 and keeps an Outperform rating on the shares. Terns reported an interim update on TERN-701's Phase 1 study in chronic myeloid leukemia, providing "encouraging" three month efficacy and safety data that reinforce confidence surrounding its differentiated profile over existing tyrosine kinase inhibitors, the analyst tells investors in a research note. The firm believes TERN-701's emerging profile supports development in earlier-line settings, and its three-month performance strengthens its optimism surrounding longer-term major molecular response data, expected in Q4 of 2025.
JMP Securities
Silvan Tuerkcan
Buy
Reiterates
$20
2024-12-04
Reason
JMP Securities
Silvan Tuerkcan
Price Target
$20
2024-12-04
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN.O) is -5.27, compared to its 5-year average forward P/E of -4.50. For a more detailed relative valuation and DCF analysis to assess Terns Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.50
Current PE
-5.27
Overvalued PE
-2.36
Undervalued PE
-6.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.64
Current EV/EBITDA
-1.79
Overvalued EV/EBITDA
1.31
Undervalued EV/EBITDA
-4.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
11.24
Current PS
0.00
Overvalued PS
58.02
Undervalued PS
-35.54
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+7.23%
-27.38M
Operating Profit
FY2025Q2
YoY :
+5.97%
-24.09M
Net Income after Tax
FY2025Q2
YoY :
-16.13%
-0.26
EPS - Diluted
FY2025Q2
YoY :
+16.60%
-18.88M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.6K
USD
1
3-6
Months
2.4K
USD
1
6-9
Months
211.1K
USD
5
0-12
Months
282.4K
USD
2
Bought
0-3
4
186.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
110.5K
USD
Months
0-12
3
5.0M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.3M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
24.6K
Volume
Months
6-9
3
2.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.6K
USD
1
3-6
Months
2.4K
USD
1
6-9
Months
211.1K
USD
5
0-12
Months
282.4K
USD
2
Bought
0-3
4
186.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
110.5K
USD
Months
0-12
3
5.0M
USD
Months
TERN News & Events
Events Timeline
2025-08-05 (ET)
2025-08-05
16:43:32
Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)
2025-05-08 (ET)
2025-05-08
16:52:03
Terns Pharmaceuticals reports Q1 EPS (26c), consensus (27c)
2025-03-20 (ET)
2025-03-20
16:36:13
Terns Pharmaceuticals reports Q4 EPS (24c), consensus (30c)
Sign Up For More Events
Sign Up For More Events
News
9.0
08-07BenzingaEli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
9.5
08-05NASDAQ.COMTerns Pharmaceuticals, Inc. Loss At -$24.09 Mln In Q2
5.0
06-26NASDAQ.COMThursday 6/26 Insider Buying Report: CCIF, TERN
Sign Up For More News
People Also Watch
JMIA
Jumia Technologies AG
7.250
USD
+12.58%
HOUS
Anywhere Real Estate Inc
5.330
USD
+2.50%
LND
BrasilAgro - Companhia Brasileira de Propriedades Agricolas
3.740
USD
+3.89%
CYRX
Cryoport Inc
8.490
USD
+4.94%
HLLY
Holley Inc
3.390
USD
+4.95%
ZEUS
Olympic Steel Inc
32.050
USD
+3.29%
AMPX
Amprius Technologies Inc
7.760
USD
+0.91%
NYXH
Nyxoah SA
6.690
USD
-4.70%
HBCP
Home Bancorp Inc
52.870
USD
+4.10%
FAQ
What is Terns Pharmaceuticals Inc (TERN) stock price today?
The current price of TERN is 6.53 USD — it has increased 3.65 % in the last trading day.
What is Terns Pharmaceuticals Inc (TERN)'s business?
What is the price predicton of TERN Stock?
What is Terns Pharmaceuticals Inc (TERN)'s revenue for the last quarter?
What is Terns Pharmaceuticals Inc (TERN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Terns Pharmaceuticals Inc (TERN)'s fundamentals?
How many employees does Terns Pharmaceuticals Inc (TERN). have?